Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Panelists Lindy Li, Siaka Massaquoi and Erin Perrine join ‘Fox News @ Night’ to discuss the top political headlines from the ...
Washington senior wide receiver Jeremiah Hunter speaks during fall camp about why he chose UW and his thoughts on the new ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
President Joe Biden finally got around to answering a series of questions from reporters about the November election loss and ...
A viral outbreak in China sounds alarmingly familiar to 2019, back in the days before most of us had ever heard of the ...
In the wake of the debacle known as the Biden presidency, certain media commentators who supported Biden and looked the other ...
Sen. Richard Blumenthal declared that the political battle is just starting after certification of President-elect Donald ...